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Numerical estimation of the variance of the completeness index  





Cancer prevalence is the proportion of people in a population diagnosed with cancer in 
the past and still alive. One way to estimate prevalence is via population-based 
registries, where data on diagnosis and life status of all incident cases occurring in the 
covered population are collected. In this report a numerical method for the estimation of 
the variance of the completeness index (NUMCOMP) is developed, and comparisons 
are made with a previous analytical method (VARCOMP) proposed by Gigli et 
al.(2006). 
The paper is organized as follows: section 1 introduces the problem; section 2 illustrates 
the new method; section 3 describes the algorithm in details; finally in section 4 the new 
and old methods are applied to the following cancer sites: all sites, anus, brain, 
colorectal for males and females, and to breast cancer for females (all races/ethnicities) 
and results are compared and commented. 
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The Surveillance, Epidemiology, and End Results (SEER) Program of the
National Cancer Institute annually reports the number of persons alive fol-
lowing a diagnosis of cancer, or complete prevalence of cancer. This statistic
is estimated in 2 steps:
1. The number of alive cancer cases reported to the SEER data after 1975
are counted and survivors among people lost to follow-up are estimated
and added. This is denoted limited duration prevalence and can be
calculated using the SEER*Stat software.
2. The proportion of prevalence that is unobserved, i.e. prevalence of
cases diagnosed prior to 1975, is estimated using the completeness in-
dex method. Limited duration prevalence is adjusted to represent com-
plete prevalence or lifetime prevalence. The completeness index method
(Capocaccia and De Angelis, 1997) is implemented into COMPREV, a
new software that calculates complete prevalence by adjusting limited
duration prevalence imported from SEER*Stat with the completeness
index.
Variance of limited duration prevalence is given in Clegg et al.(2002), vari-
ance of the completeness index (VARCOMP) and consequently of complete
prevalence is given in Gigli et al.(2006). VARCOMP is based on analytical
approximation of the variance and is implemented in the COMPREV soft-
ware. From a practical point of view VARCOMP has a limitation: since
the completeness index method, used to estimate complete prevalence, is
based on the parametric modelling of the incidence and survival functions,
VARCOMP is based on analytical derivatives of the completeness index with
respect to the incidence and survival parameters. Thus it depends on the
analytical models used to estimate incidence and survival. Experience has
shown that a single parametric form of survival and/or incidence functions
is not able to fit all different cancer sites; for example, for acute lymphocytic
leukemia we need a survival function by at least two age groups, to describe
the childhood and adult acute lymphocytic leukemia survival.
Therefore it is necessary to develop an approximation to VARCOMP
which is independent of the parametric assumptions.
In this report a numerical method for the estimation of the variance of the
completeness index (NUMCOMP) is developed, and comparisons are made
with the old method.
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The paper is structured as follows: section 2 illustrates the new method;
section 3 describes the algorithm in details; finally in section 4 the new
and old methods are applied to the following cancer sites: all sites, anus,
brain, colorectal for males and females, and to breast cancer for females (all
races/ethnicities); results are compared.
2 Numerical estimation of the variance of the
completeness index
We briefly recall some notation and the previous method (VARCOMP); fur-
ther details can be found in Gigli et al.(2006).
For a fixed birth cohort c and a fixed age at prevalence x
• complete prevalence Nx(0, x) is defined as the portion of people aged x
alive on a certain date who had been diagnosed of the disease between
ages 0 and x;
• limited duration prevalence N˜x(x− L, x) is the prevalence at age x es-
timated by population-based cancer registries and is based on a limited
observational period L (Gail et al., 1999);
• modelled prevalence Nˆx(0, x; ψˆ) is a parametric estimate of the preva-
lence at age x, based on a complex function (convolution) of incidence
and survival parametric models; ψˆ is the maximum likelihood estimate
of the vector of the incidence and survival parameters (Verdecchia et
al., 1989);
• completeness index Rx(L; ψˆ) = Nˆx(x− L, x; ψˆ)
Nˆx(0, x; ψˆ)
is the proportion of
modelled prevalence at age x that is observed (Capocaccia and De
Angelis, 1997);
• an estimate of the complete prevalence at age x is obtained by combin-
ing the limited duration prevalence and the completeness index




• the analytical approximation to the variance of the completeness index
is













where Vˆ is the covariance matrix of the mle vector ψˆ and ∂Rx/∂ψ is
the vector of partial derivatives of Rx with respect to the components
of the parameter vector ψ (Gigli et al., 2006);
Equation (1) corresponds to the diagonal of the covariance matrix ofRx(L; ψˆ).
In this report we will estimate the whole covariance matrix of the complete-
ness indices computed at different ages













The computation of ∂Rxi/∂ψ for each component of ψ and for each age group
xi is to be solved by means of successive iterations.
Let ψˆ = (ψˆ1, . . . , ψˆp) = (ψ
(0)
1 , . . . , ψ
(0)
p ) represent the 0-th iteration of the
vector of maximum likelihood incidence and survival estimates.
For a given age at prevalence xi and parameter estimate ψˆs, we apply the










where h(k)s is the k-th increment from the original s-th parameter estimate:
ψ(0)s + h
(k)





) is the completeness index computed





1 , . . . , ψ
(0)
s +
h(k)s , . . . , ψ
(0)
p ). Notice that in R
(k)+
i,s first subscript refers to age group, sec-
ond subscript refers to the iterating parameter component, superscript refers
to iteration number, + or - refer to right or left iteration.
For fixed ǫ and δ, when
|∆(k)+i,s −∆(k−1)+i,s | < ǫ (1st condition)
we have reached convergence and ∆
(k)+
i,s could be the derivative;
we further verify the continuity of the derivative by checking if the right and
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the left derivative coincide













) is the complete-
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s − h(k)s , . . . , ψ(0)p ).




i,s are the same, the
second condition becomes:
|R(k)+i,s − R(k)−i,s | < δ.
If both condition holds, the approximation to the derivative related to the









If not, we proceed with a further iteration, by setting h(k+1)s = h
(k)
s /2.
We repeat the procedure for every parameter ψˆs and every age group xi, to
compute the whole covariance matrix (2). Therefore the numerical approxi-










where ∆(k)+x is a vector of numerical approximations to the partial derivatives
of Rx with respect to the components of the vector ψ.
3 The algorithm
1. Input:
a) the number of parameters p;
b) the number of age classes n;
c) the length of the registry L;
d) the maximum likelihood estimates of incidence and survival param-
eters: ψ(0) = (ψˆ1, . . . , ψˆs, . . . , ψˆp);
e) the covariance matrix of the mle: V = cov(ψ(0)).
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2. Fix the age at prevalence xi and the component ψˆs of the vector ψ
(0)
3. Compute Rxi = Rxi(L;ψ
(0)), the original completeness index
4. Fix k = 1, ǫ = δ = 10−6
5. Fix h(1)s = sd(ψ
(0)
s )/100, i.e. one-hundredth of the standard deviation









s , . . . , ψ
(0)
p ) - where only the s-th














9. Let k → k + 1
































1 , . . . , ψ
(0)







17. If |R(k)+i,s − R(k)−i,s | ≥ δ then goto 9
18. The s-th partial derivative of Rxi is:
∂Rxi
∂ψs
∣∣∣ψs=ψˆs = ∆(k)+i,s .
Repeat 2–17 for each parameter ψs ∈ (ψ1, . . . , ψp) and for each age
group xi ∈ (x1, . . . , xn).
19. Compute cov(Ri, Rj) as in formula (2):









The algorithm has been applied to the following cancer sites: all sites, anus,
brain, colorectal for males and females, and to breast cancer for females (all
races/ethnicities). Data come from the SEER-9 registries and refer to the
period 1975–1999 (i.e. 25 years of observations).
To evaluate the performances of the old and new estimator two indicators
are used:
1. the coefficient of variation (CV), which is the ratio between the stan-






CVx is a dimensionless indicator, independent of the sample size. It is
computed for analytical and numerical standard deviations which are

















this is not a dimensionless indicator and may depend on the sample
size, however it provides an idea of the relative difference between the
two standard deviations.
Tables 1–9 describe the results for 5-year age classes.
The agreement between the two estimators is quite satisfactory, with the
exception of brain cancer (tables 5 and 6), for which further investigation is
required.
The numerical estimator is systematically smaller than the analytical
estimator (hence %diff ≥ 0), however the difference of the coefficient of
A.Gigli 7
variations is very small (never larger than O(10−4)). The maximum difference
between the standard deviations (in percentage) is generally less than 2% and
varies between 1.03% for anus cancer males and 18.87% for all sites cancer
females (in older ages, where data is scarcer and variance is wider).
Brain cancer has a completely different behaviour: both analytical and
numerical standard deviations are very high and very different between them-
selves. Although data on brain cancer is quite scarse, this alone does not ex-
plains the phenomenon. Further study is necessary to evaluate the goodness-
of-fit of the incidence and survival models, which provide the basis for the
standard deviation calculations.
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Table 1: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on male all sites cancer, SEER-9 registries in period 1975-1999.
age interval R sˆd s˜d ∆CV %diff
0 1.00 0.00 0.00 0.0000000 0.00
1–4 1.00 0.00 0.00 0.0000000 0.00
5–9 1.00 0.00 0.00 0.0000000 0.00
10–14 1.00 0.00 0.00 0.0000000 0.00
15–19 1.00 0.00 0.00 0.0000000 0.00
20–24 1.00 0.00 0.00 0.0000000 0.00
25–29 0.95 0.74 0.74 0.0000000 0.00
30–34 0.93 1.11 1.11 0.0000011 0.01
35–39 0.93 0.96 0.96 0.0000032 0.03
40–44 0.94 0.72 0.72 0.0000043 0.06
45–49 0.94 0.50 0.50 0.0000053 0.10
50–54 0.95 0.33 0.33 0.0000063 0.18
55–59 0.96 0.22 0.22 0.0000083 0.37
60–64 0.97 0.15 0.15 0.0000104 0.66
65–69 0.97 0.12 0.12 0.0000113 0.91
70–74 0.97 0.11 0.11 0.0000165 1.43
75–79 0.96 0.12 0.12 0.0000238 1.90
80–84 0.95 0.15 0.15 0.0000388 2.47
85+ 0.94 0.20 0.20 0.0000533 2.48
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Table 2: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on female all sites cancer, SEER-9 registries in period 1975-1999.
age interval R sˆd s˜d ∆CV %diff
0 1.00 0.00 0.00 0.0000000 0.00
1–4 1.00 0.00 0.00 0.0000000 0.00
5–9 1.00 0.00 0.00 0.0000000 0.00
10–14 1.00 0.00 0.00 0.0000000 0.00
15–19 1.00 0.00 0.00 0.0000000 0.00
20–24 1.00 0.00 0.00 0.0000000 0.00
25–29 0.94 0.03 0.03 0.0000074 2.17
30–34 0.91 0.04 0.04 0.0000055 1.17
35–39 0.92 0.08 0.08 0.0000076 0.85
40–44 0.93 0.09 0.09 0.0000183 1.89
45–49 0.93 0.09 0.08 0.0000300 3.20
50–54 0.93 0.09 0.08 0.0000397 4.32
55–59 0.92 0.09 0.08 0.0000541 5.61
60–64 0.91 0.10 0.09 0.0000780 7.16
65–69 0.89 0.12 0.11 0.0001186 9.10
70–74 0.87 0.14 0.13 0.0001845 11.36
75–79 0.85 0.18 0.15 0.0002876 13.86
80–84 0.82 0.22 0.18 0.0004444 16.52
85+ 0.79 0.28 0.23 0.0006667 18.87
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Table 3: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on male anus cancer, SEER-9 registries in period 1975-1999.
age interval R sˆd s˜d ∆CV %diff
0 1.00 0.00 0.00 0.0000000 0.00
1–4 1.00 0.00 0.00 0.0000000 0.00
5–9 1.00 0.00 0.00 0.0000000 0.00
10–14 1.00 0.00 0.00 0.0000000 0.00
15–19 1.00 0.00 0.00 0.0000000 0.00
20–24 1.00 0.00 0.00 0.0000000 0.00
25–29 1.00 0.00 0.00 0.0000000 0.00
30–34 1.00 0.01 0.01 0.0000000 0.00
35–39 1.00 0.05 0.05 0.0000000 0.00
40–44 0.99 0.13 0.13 0.0000010 0.08
45–49 0.98 0.23 0.23 0.0000031 0.13
50–54 0.97 0.35 0.35 0.0000082 0.23
55–59 0.96 0.47 0.47 0.0000157 0.32
60–64 0.94 0.60 0.59 0.0000266 0.42
65–69 0.92 0.71 0.71 0.0000412 0.53
70–74 0.90 0.82 0.82 0.0000597 0.65
75–79 0.89 0.93 0.92 0.0000824 0.78
80–84 0.87 1.03 1.02 0.0001072 0.90
85+ 0.85 1.13 1.12 0.0001366 1.03
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Table 4: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on female anus cancer, SEER-9 registries in period 1975-1999.
age interval R sˆd s˜d ∆CV %diff
0 1.00 0.00 0.00 0.0000000 0.00
1–4 1.00 0.00 0.00 0.0000000 0.00
5–9 1.00 0.00 0.00 0.0000000 0.00
10–14 1.00 0.00 0.00 0.0000000 0.00
15–19 1.00 0.00 0.00 0.0000000 0.00
20–24 1.00 0.00 0.00 0.0000000 0.00
25–29 1.00 0.00 0.00 0.0000000 0.00
30–34 1.00 0.00 0.00 0.0000000 0.00
35–39 1.00 0.03 0.03 0.0000000 0.00
40–44 0.99 0.08 0.08 0.0000000 0.00
45–49 0.99 0.15 0.15 0.0000000 0.00
50–54 0.98 0.23 0.23 0.0000031 0.13
55–59 0.96 0.32 0.32 0.0000083 0.25
60–64 0.95 0.40 0.40 0.0000168 0.40
65–69 0.94 0.49 0.49 0.0000353 0.68
70–74 0.92 0.57 0.57 0.0000652 1.05
75–79 0.91 0.65 0.64 0.0001115 1.55
80–84 0.89 0.73 0.72 0.0001796 2.18
85+ 0.88 0.82 0.79 0.0002804 3.01
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Table 5: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on male brain cancer, SEER-9 registries in period 1975-1999.
age interval R sˆd s˜d ∆CV %diff
0 1.00 0.00 0.00 0.0000000 0.00
1–4 1.00 0.00 0.00 0.0000000 0.00
5–9 1.00 0.00 0.00 0.0000000 0.00
10–14 1.00 0.00 0.00 0.0000000 0.00
15–19 1.00 0.00 0.00 0.0000000 0.00
20–24 1.00 0.00 0.00 0.0000000 0.00
25–29 0.91 0.43 0.43 0.0000154 0.33
30–34 0.77 0.93 0.90 0.0002978 2.48
35–39 0.71 1.23 1.16 0.0009658 5.61
40–44 0.70 1.44 1.30 0.0019874 9.65
45–49 0.71 1.64 1.41 0.0033209 14.27
50–54 0.72 1.89 1.53 0.0050651 19.36
55–59 0.74 2.23 1.67 0.0075037 25.02
60–64 0.76 2.69 1.84 0.0111398 31.42
65–69 0.77 3.35 2.05 0.0169049 38.94
70–74 0.79 4.35 2.26 0.0265148 47.98
75–79 0.80 5.93 2.46 0.0432398 58.54
80–84 0.82 8.72 2.63 0.0739977 69.88
85+ 0.85 14.38 3.02 0.1343128 79.01
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Table 6: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on female brain cancer, SEER-9 registries in period 1975-1999.
age interval R sˆd s˜d ∆CV %diff
0 1.00 0.00 0.00 0.0000000 0.00
1–4 1.00 0.00 0.00 0.0000000 0.00
5–9 1.00 0.00 0.00 0.0000000 0.00
10–14 1.00 0.00 0.00 0.0000000 0.00
15–19 1.00 0.00 0.00 0.0000000 0.00
20–24 1.00 0.00 0.00 0.0000000 0.00
25–29 0.90 0.49 0.49 0.0000212 0.39
30–34 0.74 1.01 0.99 0.0003047 2.23
35–39 0.68 1.39 1.32 0.0009660 4.76
40–44 0.68 1.78 1.60 0.0025918 9.87
45–49 0.70 2.31 1.89 0.0060049 18.28
50–54 0.74 3.04 2.12 0.0122441 30.03
55–59 0.79 3.97 2.22 0.0221362 43.97
60–64 0.83 5.14 2.16 0.0360449 57.96
65–69 0.86 6.65 2.00 0.0542797 69.99
70–74 0.88 8.72 1.81 0.0783444 79.20
75–79 0.90 11.89 1.68 0.1132879 85.91
80–84 0.92 17.57 1.61 0.1740393 90.86
85+ 0.93 30.40 1.72 0.3096149 94.35
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Table 7: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on female breast cancer, SEER-9 registries in period 1975-1999.
age interval R sˆd s˜d ∆CV %diff
0 1.00 0.00 0.00 0.000000 0.00
14 1.00 0.00 0.00 0.000000 0.00
5–9 1.00 0.00 0.00 0.000000 0.00
1014 1.00 0.00 0.00 0.000000 0.00
1519 1.00 0.00 0.00 0.000000 0.00
2024 1.00 0.00 0.00 0.000000 0.00
2529 1.00 0.00 0.00 0.000000 0.00
3034 1.00 0.00 0.00 0.000000 0.00
35–39 1.00 0.00 0.00 0.000000 0.00
4044 1.00 0.00 0.00 0.000000 0.00
45–49 1.00 0.01 0.01 0.000000 0.00
5054 1.00 0.02 0.02 0.000000 0.00
55–59 0.99 0.04 0.04 0.000001 0.28
60–64 0.97 0.07 0.07 0.000008 1.20
65–69 0.94 0.11 0.10 0.000026 2.28
7074 0.91 0.14 0.14 0.000057 3.62
75–79 0.88 0.18 0.17 0.000107 5.37
8084 0.86 0.21 0.19 0.000175 7.29
85+ 0.83 0.25 0.22 0.000252 8.51
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Table 8: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on male colorectal cancer, SEER-9 registries in period 1975-1999.
0 1.00 0.00 0.00 0.0000000 0.00
14 1.00 0.00 0.00 0.0000000 0.00
5–9 1.00 0.00 0.00 0.0000000 0.00
1014 1.00 0.00 0.00 0.0000000 0.00
1519 1.00 0.00 0.00 0.0000000 0.00
2024 1.00 0.00 0.00 0.0000000 0.00
2529 1.00 0.00 0.00 0.0000000 0.00
3034 1.00 0.00 0.00 0.0000000 0.00
35–39 1.00 0.00 0.00 0.0000000 0.00
4044 1.00 0.01 0.01 0.0000000 0.00
45–49 0.99 0.03 0.03 0.0000000 0.00
5054 0.98 0.04 0.04 0.0000000 0.00
55–59 0.97 0.06 0.06 0.0000000 0.00
60–64 0.96 0.08 0.08 0.0000010 0.13
65–69 0.95 0.09 0.09 0.0000021 0.21
7074 0.94 0.11 0.11 0.0000032 0.27
75–79 0.93 0.12 0.12 0.0000054 0.40
8084 0.92 0.14 0.14 0.0000087 0.59
85+ 0.91 0.15 0.15 0.0000121 0.75
A.Gigli 16
Table 9: Completeness index, analytical and numerical standard deviation, ∆CV ,
%diff. Data on female colorectal cancer, SEER-9 registries in period 1975-1999.
age interval R sˆd s˜d ∆CV %diff
0 1.00 0.00 0.00 0.0000000 0.00
1–4 1.00 0.00 0.00 0.0000000 0.00
5–9 1.00 0.00 0.00 0.0000000 0.00
10–14 1.00 0.00 0.00 0.0000000 0.00
15–19 1.00 0.00 0.00 0.0000000 0.00
20–24 1.00 0.00 0.00 0.0000000 0.00
25–29 1.00 0.00 0.00 0.0000000 0.00
30–34 1.00 0.00 0.00 0.0000000 0.00
35–39 1.00 0.01 0.01 0.0000000 0.00
40–44 0.99 0.02 0.02 0.0000000 0.00
45–49 0.99 0.04 0.04 0.0000000 0.00
50–54 0.97 0.06 0.06 0.0000010 0.17
55–59 0.96 0.08 0.08 0.0000000 0.00
60–64 0.95 0.10 0.10 0.0000011 0.10
65–69 0.93 0.12 0.12 0.0000021 0.17
70–74 0.92 0.14 0.14 0.0000033 0.22
75–79 0.90 0.15 0.15 0.0000055 0.33
80–84 0.89 0.17 0.17 0.0000079 0.42
85+ 0.87 0.18 0.18 0.0000114 0.55
